Table 1.
Summary of demographic and baseline characteristics, and medical comorbidities associated to hypercalcemia according to FHH-genotype
| FHH-negative (n = 36, 54.5%) |
FHH-positive (n = 30, 45.5%) |
p | |
|---|---|---|---|
| Demographical and baseline characteristics | |||
| Sex (Male/Female), n (%) | 18 (50%)/18 (50%) | 9 (30%)/21 (70%) | 0.13 |
| Age at diagnosis (years) | 67.4 (23.9) | 56.1 (24.6) | 0.03 |
| Time elapsed from hypercalcemia diagnosis to genetic study (years) | 3.4 (6.8) | 5.7 (8.7) | 0.06 |
| Family history, n (%) | 8 (22%) | 20 (67%) | <0.001 |
| Medical comorbidities | |||
| Kidney stones, n (%) | 14 (39%) | 3 (10%) | 0.01 |
| Diagnosis of osteopenia, n (%) | 15 (42%) | 8 (27%) | 0.29 |
| Diagnosis of osteoporosis, n (%) | 11 (31%) | 6 (20%) | 0.41 |
| Fragility fractures, n (%) | 3 (8%) | 0 (0%) | 0.24 |
| History of pancreatitis, n (%) | 1 (3%) | 1 (3%) | 1.00 |
| Prevalence of cardiovascular disease, n (%) | 17 (47%) | 9 (30%) | 0.21 |
| Neuropsychiatric disease, n (%) | 6 (17%) | 3 (10%) | 0.49 |
Data are reported as median (p25-p75) (non-Gaussian distribution)
FHH familial hypocalciuric hypercalcemia